274 related articles for article (PubMed ID: 25101911)
41. Variable signaling activity by FOP ACVR1 mutations.
Haupt J; Xu M; Shore EM
Bone; 2018 Apr; 109():232-240. PubMed ID: 29097342
[TBL] [Abstract][Full Text] [Related]
42. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization.
Shen Q; Little SC; Xu M; Haupt J; Ast C; Katagiri T; Mundlos S; Seemann P; Kaplan FS; Mullins MC; Shore EM
J Clin Invest; 2009 Nov; 119(11):3462-72. PubMed ID: 19855136
[TBL] [Abstract][Full Text] [Related]
43. Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.
Shore EM; Kaplan FS
Curr Osteoporos Rep; 2011 Jun; 9(2):83-8. PubMed ID: 21340697
[TBL] [Abstract][Full Text] [Related]
44. ACVR1 Function in Health and Disease.
Valer JA; Sánchez-de-Diego C; Pimenta-Lopes C; Rosa JL; Ventura F
Cells; 2019 Oct; 8(11):. PubMed ID: 31683698
[No Abstract] [Full Text] [Related]
45. The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call.
Towler OW; Shore EM; Xu M; Bamford A; Anderson I; Pignolo RJ; Kaplan FS
Eur J Med Genet; 2017 Jul; 60(7):399-402. PubMed ID: 28473268
[TBL] [Abstract][Full Text] [Related]
46. Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification.
Hamasaki M; Hashizume Y; Yamada Y; Katayama T; Hohjoh H; Fusaki N; Nakashima Y; Furuya H; Haga N; Takami Y; Era T
Stem Cells; 2012 Nov; 30(11):2437-49. PubMed ID: 22949078
[TBL] [Abstract][Full Text] [Related]
47. A blocking monoclonal antibody reveals dimerization of intracellular domains of ALK2 associated with genetic disorders.
Katagiri T; Tsukamoto S; Kuratani M; Tsuji S; Nakamura K; Ohte S; Kawaguchi Y; Takaishi K
Nat Commun; 2023 May; 14(1):2960. PubMed ID: 37231012
[TBL] [Abstract][Full Text] [Related]
48. Constitutively active ALK2 receptor mutants require type II receptor cooperation.
Bagarova J; Vonner AJ; Armstrong KA; Börgermann J; Lai CS; Deng DY; Beppu H; Alfano I; Filippakopoulos P; Morrell NW; Bullock AN; Knaus P; Mishina Y; Yu PB
Mol Cell Biol; 2013 Jun; 33(12):2413-24. PubMed ID: 23572558
[TBL] [Abstract][Full Text] [Related]
49. Patients with ACVR1
Kou S; De Cunto C; Baujat G; Wentworth KL; Grogan DR; Brown MA; Di Rocco M; Keen R; Al Mukaddam M; le Quan Sang KH; Masharani U; Kaplan FS; Pignolo RJ; Hsiao EC
Orphanet J Rare Dis; 2020 Jul; 15(1):193. PubMed ID: 32727600
[TBL] [Abstract][Full Text] [Related]
50. AMPK downregulates ALK2 via increasing the interaction between Smurf1 and Smad6, leading to inhibition of osteogenic differentiation.
Lin H; Ying Y; Wang YY; Wang G; Jiang SS; Huang D; Luo L; Chen YG; Gerstenfeld LC; Luo Z
Biochim Biophys Acta Mol Cell Res; 2017 Dec; 1864(12):2369-2377. PubMed ID: 28847510
[TBL] [Abstract][Full Text] [Related]
51. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
Ravazzolo R; Cappato S; Bocciardi R
Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
[TBL] [Abstract][Full Text] [Related]
52. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
53. Bis-Heteroaryl Pyrazoles: Identification of Orally Bioavailable Inhibitors of Activin Receptor-Like Kinase-2 (R206H).
Sekimata K; Sato T; Sakai N; Watanabe H; Mishima-Tsumagari C; Taguri T; Matsumoto T; Fujii Y; Handa N; Honma T; Tanaka A; Shirouzu M; Yokoyama S; Miyazono K; Hashizume Y; Koyama H
Chem Pharm Bull (Tokyo); 2019; 67(3):224-235. PubMed ID: 30828000
[TBL] [Abstract][Full Text] [Related]
54. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.
Song GA; Kim HJ; Woo KM; Baek JH; Kim GS; Choi JY; Ryoo HM
J Biol Chem; 2010 Jul; 285(29):22542-53. PubMed ID: 20463014
[TBL] [Abstract][Full Text] [Related]
55. Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells.
Sánchez-Duffhues G; Williams E; Benderitter P; Orlova V; van Wijhe M; Garcia de Vinuesa A; Kerr G; Caradec J; Lodder K; de Boer HC; Goumans MJ; Eekhoff EMW; Morales-Piga A; Bachiller-Corral J; Koolwijk P; Bullock AN; Hoflack J; Ten Dijke P
JBMR Plus; 2019 Nov; 3(11):e10230. PubMed ID: 31768489
[TBL] [Abstract][Full Text] [Related]
56. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
Chakkalakal SA; Shore EM
Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
[TBL] [Abstract][Full Text] [Related]
57. Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish.
Allen RS; Tajer B; Shore EM; Mullins MC
Elife; 2020 Sep; 9():. PubMed ID: 32897189
[TBL] [Abstract][Full Text] [Related]
58. ALK2 Receptor Kinase Association with FKBP12.6 Is Structurally Conserved with the ALK2-FKBP12 Complex.
Williams E; Riesebos E; Kerr G; Bullock AN
Biomedicines; 2021 Jan; 9(2):. PubMed ID: 33572801
[TBL] [Abstract][Full Text] [Related]
59. Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva.
Le VQ; Wharton KA
Dev Dyn; 2012 Jan; 241(1):200-14. PubMed ID: 22174087
[TBL] [Abstract][Full Text] [Related]
60. ALK2 inhibitors display beneficial effects in preclinical models of
Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
Commun Biol; 2019; 2():156. PubMed ID: 31098401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]